Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.

 

Announcing our new Impact Factor: 8.728

From the Current Issue

  • Research Articles
    SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti–PD-1–Resistant Model of Non–Small Cell Lung Cancer
    Dawei Chen, Hampartsoum B. Barsoumian, Liangpeng Yang, Ahmed I. Younes, Vivek Verma, Yun Hu, Hari Menon, Mark Wasley, Fatemeh Masropour, Sara Mosaffa, Tugce Ozgen, Katherine Klein, Maria Angelica Cortez and James W. Welsh
    Cancer Immunol Res July 1 2020 8 (7) 883-894; DOI:10.1158/2326-6066.CIR-19-0744

    A triple-therapy combination leads to repolarization of M2 tumor-associated macrophages (TAMs) to M1 TAMs. As a result, this combination therapy elicits robust antitumor responses against primary NSCLC tumors and can also boost antitumor abscopal responses.

  • Priority Briefs
    Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
    Marie-Claire Wagle, Joseph Castillo, Shrividhya Srinivasan, Thomas Holcomb, Kobe C. Yuen, Edward E. Kadel, Sanjeev Mariathasan, Daniel L. Halligan, Adrian R. Carr, Max Bylesjo, Paul R. McAdam, Sarah Lynagh, Koen M. Marien, Mark Kockx, Yannick Waumans, Shih-Min A. Huang, Mark R. Lackner and Zineb Mounir
    Cancer Immunol Res July 1 2020 8 (7) 844-850; DOI:10.1158/2326-6066.CIR-19-0568

    Despite the link of tumor mutational burden with response to immunotherapy, it is not universal across tumor types. In prostate cancer, the burden of tumor gene fusions positively correlates with antitumor immunity, inversely correlating with tumor mutational burden.

OnlineFirst Articles

Load more
Advertisement

Back to top